Cidara Therapeutics (CDTX) Reaches $6.00 After 4.00% Down Move; Seneca Foods (SENEA)’s Sentiment Is 2

June 5, 2017 - By Kurt Siggers

Seneca Foods Corporation is a provider of packaged fruits and vegetables. The company has market cap of $301.29 million. The Firm manages its business through two divisions: packaging and sale of fruits and vegetables, and packaging and sale of chip products. It has a 24.4 P/E ratio. The Company’s product offerings include canned fruits and vegetables, frozen vegetables and other food products, frozen and bottled produce, and snack chips.

The stock of Cidara Therapeutics Inc (NASDAQ:CDTX) is a huge mover today! About 50,360 shares traded. Cidara Therapeutics Inc (NASDAQ:CDTX) has declined 38.96% since June 5, 2016 and is downtrending. It has underperformed by 55.66% the S&P500.The move comes after 7 months negative chart setup for the $102.46M company. It was reported on Jun, 5 by Barchart.com. We have $5.76 PT which if reached, will make NASDAQ:CDTX worth $4.10M less.

Since January 1, 0001, it had 0 insider buys, and 1 insider sale for $2,000 activity.

About 24,456 shares traded or 39.52% up from the average. Seneca Foods Corp (SENEA) has risen 14.82% since June 5, 2016 and is uptrending. It has underperformed by 1.88% the S&P500.

Analysts await Seneca Foods Corp (NASDAQ:SENEA) to report earnings on June, 14.

P.R. Herzig & Co. Inc. holds 6.23% of its portfolio in Seneca Foods Corp for 76,150 shares. Capital Impact Advisors Llc owns 26,308 shares or 0.44% of their US portfolio. Moreover, Robotti Robert has 0.21% invested in the company for 17,182 shares. The Maryland-based Advisors Preferred Llc has invested 0.2% in the stock. Shufro Rose & Co Llc, a New York-based fund reported 37,950 shares.

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The company has market cap of $102.46 million. The Firm is engaged in the discovery, development and commercialization of anti-infectives. It currently has negative earnings. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Among 4 analysts covering Cidara Therapeutics (NASDAQ:CDTX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Cidara Therapeutics had 5 analyst reports since October 9, 2015 according to SRatingsIntel. Leerink Swann reinitiated the shares of CDTX in report on Wednesday, December 21 with “Outperform” rating. As per Friday, September 23, the company rating was downgraded by WBB Securities. On Monday, December 19 the stock rating was initiated by H.C. Wainwright with “Buy”. The stock of Cidara Therapeutics Inc (NASDAQ:CDTX) has “Hold” rating given on Friday, October 9 by WBB Securities.